Regions With Risk Of
Malaria (H - L)
Haiti
Malaria risk—exclusively due to P. falciparum—exists throughout the year in certain forest areas in Chantal, Gros Morne, Hinche, Jacmel and Maissade. In the other cantons, risk is estimated to be low. No P. falciparum resistance to chloroquine reported.
Honduras
Malaria risk—predominantly due to P. vivax—is high throughout the year in 223 municipalities. Transmission risk is low in the other 71 municipalities, including San Pedro Sula and the city of Tegucigalpa. P. falciparum risk is the highest in Sanitary Region VI, including in the Islas de la Bahía.
India
Malaria risk exists throughout the year in the whole country below 2000 m. There is no transmission in parts of the states of Himachal Pradesh, Jammu and Kashmir, and Sikkim. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported.
Indonesia
Malaria risk exists throughout the year in the whole country except in Jakarta Municipality, big cities, and within the areas of the tourist resorts of Bali and Java. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. P. vivax resistant to chloroquine reported.
Iran, Islamic Rebublic of
Limited risk—exclusively due to P. vivax—exists in some areas north of the Zagros mountains and in western and south-western regions during the summer months. Malaria risk due to P. falciparum exists from March through November in rural areas of the provinces of Hormozgan, Kerman (tropical part) and Sistan–Baluchestan. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported.
Iraq
Malaria risk—exclusively due to P. vivax—exists from May through November, principally in areas in the north below 1500 m (Duhok, Erbil, Ninawa, Sulaimaniya and Ta'mim provinces) but also in Basrah Province.
Kenya
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. There is normally little risk in the city of Nairobi and in the highlands (above 2500 m) of Central, Eastern, Nyanza, Rift Valley and Western provinces. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported.
Korea, Democratic People's Republic of
Limited malaria risk—exclusively due to P. vivax—exists in some southern areas.
Korea, Republic of
Limited malaria risk—exclusively due to P. vivax—exists mainly in the northern areas of Kyunggi Do Province.
Kyrgyzstan
Malaria risk – exclusively due to P. vivax – exists from June through September in some southern and western parts of the country, mainly in Batken, Osh and Zhele-Abadskaya provinces in areas bordering Tajikistan and Uzbekistan.
Lao People's Democratic Republic
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country except in Vientiane. Chloroquine-resistant P. falciparum reported.
Liberia
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported.
| A - B | C | D - G | H - L | M - O | P - S | T - Z | Return to the country list |
World Health Organization. International Travel and Health 2003. Geneva, Switzerland.

Important Information
There are four types of malaria. MALARONE is approved for the treatment and prevention of Plasmodium falciparum malaria in adults and children weighing at least 25 lbs.
In studies conducted for the prevention of malaria in adults, the most common side effects possibly attributed to MALARONE versus placebo were headache (5% vs. 7%) and abdominal pain (3% vs. 5%), in pediatric patients, headache (14% vs. 14%), abdominal pain (31% vs. 29%), and vomiting (7% vs. 6%).
MALARONE is not for everyone. You should not take MALARONE if you have severe kidney disease or are allergic to MALARONE or any of its components. If you are pregnant, consult your physician about the risks and benefits of using MALARONE. Rare cases of anaphylaxis following treatment with atovaquone/proguanil (MALARONE) have been reported.









